Business Context and Reporting Period
Company: Champions Biotechnology, Inc. (Ticker: CSBR)
Filing Type: Form 10-K (Annual Report)
Period Ended: April 30, 2010
Business Overview: The Company develops advanced preclinical platforms and predictive tumor-specific data to accelerate oncology drug development. Its core assets include the Biomerk Tumorgraft platform (implantation of human tumors in mice) and a portfolio of four drug compounds (BPU, TAR-1, Bithionol, and Irinophore C). Revenue is generated through Personalized Oncology Services (POS) for physicians and Preclinical eValuation (PCE) services for pharmaceutical companies.
Key Financial Metrics
| Metric | Fiscal 2010 | Fiscal 2009 |
|---|---|---|
| Total Operating Revenue | $4,893,000 | $3,710,000 |
| Net Loss | $(2,923,000) | $(2,242,000) |
| Accumulated Deficit | $(12,680,000) | $(9,757,000) |
| Cash and Cash Equivalents | $2,572,000 | $1,728,000 |
| Working Capital | $1,068,000 | $1,166,000 |
| Research & Development Expenses | $2,695,000 | $1,721,000 |
| Net Cash Used in Operating Activities | $(2,100,000) | $(888,000) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 32% to $4.89 million. This was driven by a 290% surge in PCE services revenue ($1.69 million), partially offset by a 2% decline in POS revenue ($3.21 million).
- Expense Increases: Total costs and operating expenses rose 29% to $7.82 million. R&D expenses increased 57% due to licensing fees and option rights for new drug compounds. General and Administrative expenses increased 48% due to infrastructure expansion and the establishment of U.K. and Israel operations.
- Net Loss Expansion: Net loss widened by $681,000 (30%) primarily due to increased operating costs outpacing revenue growth.
- Capital Raise: The Company raised $2.25 million in gross proceeds from a private placement of 3 million shares between December 2009 and April 2010.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The independent auditor has raised substantial doubt about the Company's ability to continue as a going concern due to recurring losses and the need for additional capital to fund operations.
- Outlook: Management expects to continue incurring operating losses. The Company plans to sell, partner, or license its drug compounds rather than pursuing full commercialization internally. Preclinical testing for the fourth drug compound is expected to begin in fiscal 2011.
- Unusual Items:
- Impairment: No impairment charge in 2010; a $284,000 impairment of intangible assets (patent rights) occurred in 2009.
- Exit Costs: Approximately $58,000 in exit costs were incurred to close the Tempe, Arizona office and consolidate operations in Baltimore.
- Stock Repurchase: The Company repurchased 474,289 shares from a Board member for $218,000 under a specific agreement.
- Risks: Significant risks include the early-stage nature of drug development, dependence on third-party CROs for testing, potential dilution from future equity raises, and the "penny stock" status of its common stock which limits liquidity.
Investor Verification Checklist
- Cash Runway: Verify if the $2.57 million cash balance is sufficient to fund operations given the $2.1 million annual operating cash burn.
- Capital Requirements: Assess the likelihood and terms of future capital raises required to sustain R&D and operations.
- Revenue Concentration: Review the sustainability of the 290% growth in PCE services and the decline in POS services.
- Related Party Transactions: Scrutinize the stock repurchase agreement with the Board member and consulting fees paid to directors and significant shareholders.
- Intellectual Property: Confirm the status of the four drug compounds and the validity of the BPU patent rights following the 2009 impairment.